Published in Cell on September 02, 2011
Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72
FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol (2013) 2.83
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell (2014) 2.01
AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. Cell Stem Cell (2015) 1.51
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature (2014) 1.37
FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci (2014) 1.32
mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest (2012) 1.27
Differentiation of CD8 memory T cells depends on Foxo1. J Exp Med (2013) 1.25
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia (2013) 1.22
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol (2012) 1.21
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest (2013) 1.20
PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis (2013) 1.16
RUNX1 and its understudied role in breast cancer. Cell Cycle (2011) 1.16
Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. Mol Syst Biol (2015) 1.12
Aging-like phenotype and defective lineage specification in SIRT1-deleted hematopoietic stem and progenitor cells. Stem Cell Reports (2014) 1.12
Antagonism between FOXO and MYC Regulates Cellular Powerhouse. Front Oncol (2013) 1.10
Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis. Oncogene (2015) 1.09
Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer (2012) 1.06
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell (2014) 1.04
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML. J Exp Med (2014) 1.03
DAF-16/FOXO and EGL-27/GATA promote developmental growth in response to persistent somatic DNA damage. Nat Cell Biol (2014) 1.03
Concise review: Leukemia stem cells in personalized medicine. Stem Cells (2014) 1.02
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood (2013) 1.00
mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A (2014) 0.98
Akt-signal integration is involved in the differentiation of embryonal carcinoma cells. PLoS One (2013) 0.97
Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. Cell Stem Cell (2015) 0.96
FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ (2013) 0.95
Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. Proc Natl Acad Sci U S A (2013) 0.94
A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival. Oncogene (2014) 0.93
FOXO3: A Major Gene for Human Longevity - A Mini-Review. Gerontology (2015) 0.92
FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression. Oncogenesis (2015) 0.91
The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer. BMC Cancer (2014) 0.90
Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res (2012) 0.90
Stem cells, redox signaling, and stem cell aging. Antioxid Redox Signal (2014) 0.89
Cell-nonautonomous signaling of FOXO/DAF-16 to the stem cells of Caenorhabditis elegans. PLoS Genet (2012) 0.89
ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia. Cell Rep (2014) 0.89
Evidence for AKT-independent regulation of FOXO1 and FOXO3 in haematopoietic stem and progenitor cells. Cell Cycle (2016) 0.88
AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. Leukemia (2013) 0.87
Targeting self-renewal pathways in myeloid malignancies. Cell Commun Signal (2013) 0.87
CHIP regulates AKT/FoxO/Bim signaling in MCF7 and MCF10A cells. PLoS One (2013) 0.86
Menin as a hub controlling mixed lineage leukemia. Bioessays (2012) 0.85
Mitochondrial metabolism in hematopoietic stem cells requires functional FOXO3. EMBO Rep (2015) 0.83
Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. Genes Dev (2013) 0.83
Regulation of cell cycle progression by forkhead transcription factor FOXO3 through its binding partner DNA replication factor Cdt1. Proc Natl Acad Sci U S A (2012) 0.83
EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. PLoS One (2013) 0.83
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia (2016) 0.83
Targeted drug discovery for pediatric leukemia. Front Oncol (2013) 0.82
A Systems Approach Identifies Essential FOXO3 Functions at Key Steps of Terminal Erythropoiesis. PLoS Genet (2015) 0.81
FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression. EMBO Rep (2015) 0.81
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat (2014) 0.80
Longevity Genes Revealed by Integrative Analysis of Isoform-Specific daf-16/FoxO Mutants of Caenorhabditis elegans. Genetics (2015) 0.80
Leukaemia 'firsts' in cancer research and treatment. Nat Rev Cancer (2016) 0.79
Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma. Cell Commun Signal (2014) 0.79
Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clin (2015) 0.79
Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia (2016) 0.79
Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy. Leukemia (2016) 0.79
FOXO3 Transcription Factor Is Essential for Protecting Hematopoietic Stem and Progenitor Cells from Oxidative DNA Damage. J Biol Chem (2016) 0.78
FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice. Leukemia (2015) 0.78
A new FOXO pathway required for leukemogenesis. Cell (2011) 0.78
miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. Cell Death Dis (2016) 0.77
Molecular Basis for the Regulation of Transcriptional Coactivator p300 in Myogenic Differentiation. Sci Rep (2015) 0.77
The Tumorigenic Roles of the Cellular REDOX Regulatory Systems. Oxid Med Cell Longev (2015) 0.77
Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia. Oncotarget (2015) 0.77
Harnessing the apoptotic programs in cancer stem-like cells. EMBO Rep (2015) 0.77
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Invest (2014) 0.76
GSK3 protein positively regulates type I insulin-like growth factor receptor through forkhead transcription factors FOXO1/3/4. J Biol Chem (2014) 0.76
Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports (2014) 0.76
Retinoid X Receptor-selective Signaling in the Regulation of Akt/Protein Kinase B Isoform-specific Expression. J Biol Chem (2015) 0.76
Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells. PLoS One (2014) 0.76
New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond. Discoveries (Craiova) (2015) 0.76
The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy. J Clin Med (2015) 0.76
FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition. Oncotarget (2016) 0.75
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. J Clin Invest (2016) 0.75
miR-302 regulates pluripotency, teratoma formation and differentiation in stem cells via an AKT1/OCT4-dependent manner. Cell Death Dis (2016) 0.75
Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia. Leukemia (2016) 0.75
FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma. Oncotarget (2016) 0.75
FOXO1 inhibits osteoclastogenesis partially by antagnozing MYC. Sci Rep (2015) 0.75
C. elegans DAF-16/FOXO interacts with TGF-ß/BMP signaling to induce germline tumor formation via mTORC1 activation. PLoS Genet (2017) 0.75
Misfolded N-CoR is Linked to the Ectopic Reactivation of CD34/Flt3-Based Stem-Cell Phenotype in Promyelocytic and Monocytic Acute Myeloid Leukemia. Front Oncol (2015) 0.75
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest (2017) 0.75
A FOXO1-induced oncogenic network defines the AML1-ETO pre-leukemic program. Blood (2017) 0.75
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell (1994) 16.30
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 11.61
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev (1993) 10.01
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med (2004) 9.81
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 9.58
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature (1999) 7.66
Perturbations of the AKT signaling pathway in human cancer. Oncogene (2005) 6.64
The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal (2002) 6.35
Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 5.94
JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell (2005) 4.64
FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J (2004) 4.57
Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol (2001) 4.09
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature (2010) 3.12
FOXOs, cancer and regulation of apoptosis. Oncogene (2008) 3.02
Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol (2005) 2.94
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature (2008) 2.51
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood (2009) 2.42
Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J Biol Chem (2008) 1.95
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell (2010) 1.82
Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol (2006) 1.77
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia (2009) 1.38
Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol (2001) 1.28
MLL-rearranged leukemias: insights from gene expression profiling. Semin Hematol (2003) 1.16
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leuk Res (2009) 0.94
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
International network of cancer genome projects. Nature (2010) 20.35
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med (2004) 9.81
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Pancreatic cancer biology and genetics. Nat Rev Cancer (2002) 7.36
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet (2008) 7.30
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature (2008) 6.61
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol (2007) 5.80
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature (2005) 5.54
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
Connecting chromosomes, crisis, and cancer. Science (2002) 4.69
Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell (2012) 4.67
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell (2007) 4.59
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol (2006) 4.49
PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science (2003) 4.32
Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol (2009) 4.31
Telomeres and telomerase in cancer. Carcinogenesis (2009) 4.28
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med (2005) 4.17
Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest (2005) 4.10
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06